Topic Hub
23 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 23 of 23 clinical reviews.
A direct comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis: fracture-reduction evidence, cost, insurance access, and how to choose between them.
Read clinical reviewEvidence-based comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including ARCH trial head-to-head data, fracture reduction rates, and clinical guidance on sequencing.
Read clinical reviewA detailed comparison of Fosamax (alendronate) and Evenity (romosozumab) side effects, including GI tolerability, cardiovascular risk, ONJ, atypical fractures, and clinical guidance on switching.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and romosozumab (Evenity) for osteoporosis, including when to switch, which to use first, and what the evidence from FIT and ARCH actually shows.
Read clinical reviewA detailed comparison of Fosamax (alendronate) and Prolia (denosumab) covering price, insurance coverage, fracture efficacy data, and practical access considerations for osteoporosis treatment.
Read clinical reviewCompare Fosamax (alendronate) and Prolia (denosumab) for osteoporosis: fracture reduction data from FIT and FREEDOM trials, BMD gains, onset of action, and which drug fits which patient.
Read clinical reviewA detailed, citation-dense comparison of alendronate (Fosamax) and denosumab (Prolia) side effects, fracture efficacy, and clinical decision-making for osteoporosis treatment.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and denosumab (Prolia) for osteoporosis, with evidence-based guidance on when and how to switch between these two therapies.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) covering efficacy data, pricing, insurance coverage, generic availability, and practical access considerations for osteoporosis treatment.
Read clinical reviewEvidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, covering fracture reduction, BMD gains, dosing, side effects, and switching protocols.
Read clinical reviewA clinical comparison of alendronate (Fosamax) and zoledronic acid (Reclast) side effects, tolerability, and safety data from the FIT and HORIZON-PFT trials.
Read clinical reviewEvidence-based comparison of alendronate (Fosamax) and zoledronic acid (Reclast) for osteoporosis, including when and how to switch between these bisphosphonates.
Read clinical reviewA detailed clinical and cost comparison of denosumab (Prolia) and romosozumab (Evenity) for osteoporosis, covering fracture efficacy, mechanism of action, insurance coverage, list price, and how to choose between them.
Read clinical reviewA detailed clinical comparison of denosumab (Prolia) and romosozumab (Evenity) for osteoporosis treatment, covering fracture reduction data, BMD gains, safety profiles, and how to choose between them.
Read clinical reviewA clinical comparison of Prolia (denosumab) and Evenity (romosozumab) side effects, cardiovascular warnings, injection-site reactions, rebound fracture risk, and monitoring requirements.
Read clinical reviewClinical comparison of denosumab and romosozumab for osteoporosis, including when and how to switch between them, trial data from FREEDOM and ARCH, and sequencing strategies to protect bone density.
Read clinical reviewA direct comparison of zoledronic acid (Reclast) and romosozumab (Evenity) covering efficacy, cost, insurance access, administration, and which patients benefit most from each drug.
Read clinical reviewA clinical comparison of zoledronic acid (Reclast) and romosozumab (Evenity) for osteoporosis treatment, covering fracture reduction, BMD gains, cardiovascular safety, and sequencing strategies based on HORIZON-PFT and ARCH trial data.
Read clinical reviewA clinical comparison of the side-effect profiles of zoledronic acid (Reclast) and romosozumab (Evenity) for osteoporosis, including cardiovascular signals, acute-phase reactions, injection-site events, and rare skeletal risks.
Read clinical reviewA clinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) covering efficacy, cost, insurance coverage, generic availability, and access considerations for osteoporosis treatment.
Read clinical reviewA direct comparison of zoledronic acid (Reclast) and denosumab (Prolia) for osteoporosis: fracture reduction rates, BMD gains, mechanism, dosing, safety, and how to choose between them based on clinical evidence.
Read clinical reviewA clinical comparison of side effects between Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including acute-phase reactions, rebound fracture risk, ONJ, and long-term safety data from HORIZON-PFT and FREEDOM trials.
Read clinical reviewClinical comparison of Reclast (zoledronic acid) and Prolia (denosumab) for osteoporosis, including when and how to switch between these two bone-loss therapies safely.
Read clinical review